Oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact

BCMA CAR-T Pipeline Landscape

Focus: Multiple Myeloma Indication
Image Credit: KGH
 
Note:
  1. If you are viewing this webpage on mobile, please use Landscape mode for better visual and reading experience.
  2. You can write to us at support@oncofocus.com for any clarification

Multiple Myeloma is the second most common hematologic malignancy and is largely considered incurable. The promising results obtained with the bluebird bio’s idecabtagene vicleucel (bb2121) and Janssen - Legend Biotech’s JNJ-68284528 (LCAR-B38M) brought CAR-Ts at the forefront of the clinical research. 

B-cell Maturation Antigen (BCMA) is an antigen that has been shown to be specifically expressed in myeloma cells. With the ASH Annual Meeting 2019 close at hand, we performed a comprehensive pipeline analysis of BCMA targeting CAR-Ts in Multiple Myeloma indication.

We had ​​two specific objectives
Picture

We identified 47 BCMA targeting CAR-Ts
Our detailed analysis of clinical trials from various registries showed that 47 BCMA CAR-Ts are under clinical development by 40 companies. Idecabtagene vicleucel (ide-cel) leads the pack being the ONLY candidate in Phase 3. 

BCMA CAR-T Pipeline Landscape in Multiple Myeloma
File Size: 712 kb
File Type: png
Download File

Picture
Picture

The results from the Phase 2 CRB-401 trial, published in May 2019, showed that ide-cil offered an impressive ORR of 85%. However, the median PFS of 11.8 months somewhat disappointed experts who were expecting ide-cel to be a curative therapy.

Could combining BCMA CAR-Ts with another agent increase its efficacy? Notably, only about 30% of trials are investigating BCMA CAR-Ts in combination with another agent. In other words, about 70% of trials are studying BCMA CAR-Ts as monotherapy.

How are these BCMA targeting CAR-Ts differentiated? CAR-T design, target patient pool, or anything else? We will soon publish our findings on this question.

Picture

Are you looking for a research agency that not only reports data but also answers Why/How/When?   

Oncofocus has years of experience in providing solutions across the product lifecycle. Engage Us!

Bangalore Office
Oncofocus Solutions Pvt Ltd, 

#4, II Floor, 5th Main, 9th Cross, Jaya Mahal Ext,
Bengaluru
, India 56 00 46

Tel. +91 89044 00482

E-mail: support@oncofocus.com
RFQ: rfq@oncofocus.com
​

Singapore Office (Sales)
Oncofocus Solutions Pte Ltd, 

51 Goldhill Plaza, 
#07-10/11
​Singapore 30 89 00
​



E-mail: support@oncofocus.com.sg
​RFQ: rfq@oncofocus.com
​

    Subscribe to our Newsletter

Subscribe to Newsletter
Tweets by oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact